• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Hyderabad, Aug 4

Suven Life Sciences Ltd presented preclinical data for its lead antagonist drug candidate at the Alzheimer’s Association International Conference on Alzheimer’s disease (ICAD-2008) and Drug Discovery & Development of Innovative Therapeutics held in Chicago and Boston recently. “We are extremely pleased with the data emerging from our proprietary 5-HT6 antagonist program. SUVN-502 produces a robust effect in key models of cognition with a favourable sa fety and pharmacokinetic profile, providing a strong rationale for clinical development in a cognition indication,” Mr Venkat Jasti, Chief Executive Officer of Suven Life Sciences Ltd, said in a release. The phase I of the drug had commenced at Basel, Switzerland and were expected to be completed by Dec 2008, he added.

—Our Bureau

More Stories on : Research & Development | Pharmaceuticals | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Suven presents Alzheimer’s drug data

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line